$IRON News

Disc Medicine Presents Updated Data From Myelofibrosis And Anemia Treatment RALLY-MF Phase 2 Trial Showing Reductions In Hepcidin And Higher Iron Levels, A Positive Clinical Impact On Anemia Measures Across A Broad Range Of Patient Types

Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $80

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress

Disc Medicine to Participate in Upcoming Investor Conferences

A Look At Disc Medicine (IRON) Valuation After Legal Probes And FDA Complete Response Letter

Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update

Disc Medicine Q1 EPS $(1.65) Beats $(1.73) Estimate

Disc Medicine Insider Sells $380K in Stock Amid 70% One-Year Surge

Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting

Disc Medicine To Present Data From RALLY-MF Phase 2 Trial Of DISC-0974 In Anemia Of Myelofibrosis In Oral Abstract Session At ASCO Annual Meeting

Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria

Disc Medicine Doses Last Patient In Pivotal Phase 3 APOLLO Study Of Bitopertin In Erythropoietic Protoporphyria

Evaluating Disc Medicine (IRON) After Recent Share Moves And Conflicting Valuation Signals

Wells Fargo Maintains Overweight on Disc Medicine, Raises Price Target to $79

Disc Medicine CFO Sells $720k Worth of Shares Amid FDA Rejection

Disc Medicine (IRON) Is Up 8.6% After Wider 2025 Losses And New Shelf Registration - What's Changed

On February 26, 2026, Disc Medicine's Board Of Directors Approved A Restructuring Plan; Co. To Reduce Its Workforce By ~ 20%; Expects To Complete The Implementation Of The Restructuring Plan In Q2 Of 2026

Truist Securities Maintains Buy on Disc Medicine, Lowers Price Target to $83

Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Disc Medicine Q4 EPS $(1.62) Beats $(1.68) Estimate